The drug also showed a manageable safety profile, with just 6.4% of patients stopping treatment due to side effects. No new safety concerns emerged
The facility supports drug discovery, biomolecular research, and the development of next-generation diagnostics
Zydus has developed an innovative formulation of Semaglutide Injection in a prefilled cartridge administered using a reusable patient-friendly pen device
The deal also includes upfront licensing fees and milestone-based payments from Lupin to Zydus
The trial enrolled patients with stage IV pancreatic cancer, where median life expectancy is just 6 to 12 months
This study demonstrates the power of real-time glucose information for people with Type 2 diabetes treated with basal insulin
Lilly has long voiced concerns over mass-compounded knockoffs of its tirzepatide medicines, Mounjaro and Zepbound
Neupharma gains exclusive rights to develop and commercialize corticorelin for peritumoral brain edema
Phase I EPRAD study of DT-9081 demonstrated a favorable safety profile
Giredestrant shows promise despite missing primary goal
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
